FY2025 · ended Dec 31, 2025 · Revenue $1.40M · Filed Mar 30, 2026
Avenue Therapeutics, Inc. (ATXI) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $1.4 million and a net loss of $2.9 million.
Revenue (TTM)
$0
Net income (TTM)
$-2.78M
Operating cash flow (TTM)
$-1.38M
+72.4% vs year-ago TTM
Free cash flow
—
EPS
$-0.22
Dividend per share
None
Shares outstanding
3.29M
+4.6% vs prior year
Net cash
—
Operating margin
-219.6%
FY 2025
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ATXI (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Bay Harbor Islands, FL
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1644963
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
FY 2020 Dec 31, 2020 |
FY 2019 Dec 31, 2019 |
|---|---|---|---|---|---|
| Revenue | $1.4M | — | — | — | — |
| Operating income | -$3.1M | -$8.0M | -$3.7M | -$5.2M | -$26.3M |
| Net income | -$2.9M | -$3.6M | -$3.7M | -$5.2M | -$25.9M |
| Diluted EPS | — | — | -$0.22 | — | — |
| Operating cash flow | -$1.8M | -$7.6M | -$3.8M | -$4.6M | -$26.3M |
| Total assets | $2.9M | $6.8M | $4.0M | $3.2M | $8.9M |
| Total liabilities | $1.1M | $3.6M | $509,000 | $886,000 | $2.1M |
| Stockholders' equity | $1.8M | $3.9M | $3.5M | $2.4M | $6.8M |
| Cash and investments | $2.9M | $6.7M | $3.8M | $3.1M | $8.7M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 7, 2026 | Jun 30, 2026 |
| 10-Q | Quarterly report | May 8, 2026 | Mar 31, 2026 |
| 10-K | Annual report | Mar 30, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Material agreement, Other events
|
Feb 23, 2026 | Feb 18, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Dec 31, 2025 | Dec 30, 2025 |
| 8-K |
Current report
Other events
|
Nov 18, 2025 | Nov 14, 2025 |
All 423 Avenue Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.